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Abstract
Background: Hand, foot, and mouth disease (HFMD) has been emerging as an important public problem over the past few
decades, especially in Asian and Pacific regions. A national program on EV71 vaccine development against HFMD was
initiated in China, in 2008, which called for a need for seroepidemiological study for the target population.
Methodology/Principal Findings: This was a retrospective study conducted in Jiangsu Province, in October, 2010. We
measured the neutralizing antibodies against EV71 and CoxA16 in a cohort of infants aged of 2, 7, 12, and 27–38 months
and their mothers just before delivery. Series sera samples from 975 infants and 555 mothers were collected and analyzed.
Questionnaires on the history of HFMD were completed in the survey. A total of 143 HFMD cases were collected, but only
11.2% were reported to the National Infectious Disease Information Management System. The level of maternal antibody
titers decreased dramatically during the first 7 month and remained at a relatively low level thereafter. But it increased
significantly from month 12 to months 27–38. The accumulate incidence density of HFMD demonstrated a significant
increase after 14 months of age, resulting in a accumulate incidence density of 50.8/1000 person-years in survey period.
Seropositivity of EV71 antibody in infants at the age of 2 months seems to demonstrate a protective effect against HFMD.
Conclusions and Significance: High seropositive rate of EV71 and CoxA16 antibody was found in prenatal women in
mainland China, and there is a need to enhance the HFMD case management and the current surveillance system. We
suggest that infants aged between 6 to 14 months should have the first priority to receive EV71 vaccine.
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Introduction
In 1998, a large outbreak of hand, foot, and mouth disease
(HFMD) occurred in Taiwan [1]. A total of 129,106 cases were
reported, including 78 deaths [2–5]. In 2007, more than 80,000
HFMD cases were reported with dozens of deaths in mainland
China [6,7], which arose public concerns around HFMD.
Enterovirus 71 (EV71) and coxsackievirus A16 (CoxA16) are
two predominant pathogens causing HFMD, though EV71
contributes more to severe and fatal cases [8–10].
On May 2, 2008, HFMD was declared a type C legally
notifiable communicable disease in mainland China [6,11]. In the
same year, a national program of EV71 vaccine development
against HFMD was initiated, which required clinical trials in the
target population. Previous studies showed that the HFMD
predominantly occurred in children under 5 years old, especially
those less than 3 years old. Most adults presented with subclinical
infection when exposed to EV71 or CoxA16, and then developed
protective antibodies, which can transplacentally pass to newborns
[12–14]. These transplacental antibodies may protect young
infants from infectious EV71 or CoxA16, but they can also
impede the effectiveness of certain vaccines and confound
interpretation of vaccine-induced immune responses [4,15–17].
For this reason, a better understanding of the dynamic changes in
pathogen-specific transplacental antibody and the incidence of
HFMD in young infants will be helpful for EV71 vaccine trials
with respect to the selection of a suitable target population.
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37206Based on a cohort of healthy neonates enrolled in 2007, we
conducted a retrospective epidemiological study on HFMD and
the dynamic changes of EV71 and CoxA16 neutralizing antibod-
ies in the infant cohort.
Materials and Methods
Subjects and Study Design
In April 2007, a clinical trial titled ‘‘The Safety and
Immunogenicity of Recombinant Hepatitis B Vaccines in the
Healthy Neonates’’ (ClinicalTrials.gov ID: NCT01183611) was
performed. Parturient women and their healthy newborns were
recruited in the hospitals of six counties/districts in Jiangsu
Province of China. Blood samples were obtained from participat-
ing pregnant women before delivery and their infants at 2, 7, and
12 months of age. The first and last baby was born on September
10, 2007 and August 1, 2008, respectively.
In October 2010, we conducted a retrospective epidemiological
survey (ClinicalTrials.gov ID: NCT01255124) on the occurrence
of HFMD in the infants who had participated in the previous trial
mentioned above. Parents or guardians were asked to complete
questionnaires on their infants’ health history including the
occurrence of blister-like eruptions in the mouth, skin rashes and
fever. Associated medical records were also checked. Besides,
blood samples were collected from these infants in this survey. Plus
the stored sera from the mothers before the delivery and these
infants at 2, 7, 12 month of age from the previous trial, all the
blood samples were used to measure the EV71 and CoxA16
neutralizing antibody titers. The study was approved by the ethics
committee of the Jiangsu Provincial Center for Disease Control
and Prevention, and conducted in compliance with the principles
of the Declaration of Helsinki. Written informed consent was
obtained from the parents or legal guardians.
In this study, HFMD was defined as the occurrence of blister-
like eruptions in the mouth or on hand, foot, or buttock,
accompanied by fever in the absence of measles, rubella, chicken
pox, other febrile eruption disease, or allergy. Non-HFMD
infection with EV71 or CoxA16 was defined here as any infant
who presented no blister-like eruptions symptoms but were
seropositive for EV71 and/or CoxA16 neutralizing antibody after
12 months of age or had at least four-fold increase between the
ages of 2 and 7 months. Those infants were deemed as uninfected
who presented no HFMD symptoms and had EV71 or CoxA16
neutralizing antibody titers less than 1:8 at all the 4 time points or
the absence of a 4-fold rise between any two consecutive time
points.
The purpose of this study was to investigate the infection
spectrum of EV71 and CoxA16, the dynamic change of serum
antibodies in the infants, and the incidence of HFMD. In order to
determine the proportion of underreported HFMD in these six
counties and districts, data was also collected from the National
Infectious Disease Information Management System which is a
passive surveillance system for notifiable communicable disease,
from September 2007 through October 2010.
EV71 and CoxA16 Neutralizing Antibody Assays
For neutralizing antibody detecting in this study, EV71/
Fuyang/m01/2008 (C4 genotype) strain was used, which is the
predominant genotype in China and also used as the EV71
vaccine strain, while CoxA16/G-10 (A genotype) strain was used
to detect the CoxA16 neutralizing antibody. The capability of
cross-protection of EV71 and CoxA16 antibody has been studied
in previous researches [18,19].
To measure EV71 and CoxA16 neutralizing antibody by micro-
dose cytopathogenic effect, blood samples were initially diluted to
1:8, inactivated at 56uC for 30 minutes, then serially diluted from
1:8 to 1:2048 and mixed with equal volumes of 100 TCID50
EV71 and CoxA16. The mixture was added into a 96-well micro-
plate and incubated at 37uC for 2 hours. Finally, RD cell
suspension (16105 cells/mL) was added to the mixture. The
plates were then placed in a CO2 incubator at 35uC for 7 days,
and the cytopathogenic effect was observed under microscopy.
Cell control, serum control, virus control, and virus backdrops
were all established on each plate. If the backdrops showed 32–320
TCID50/well, the test was considered successful. Neutralizing
antibody titers were defined as the dilution rate showing 50%
inhibition on the cytopathogenic effect. This method had been
validated using reference serums of EV71 and CoxA16, and no
cross-reaction was found [20]. Neutralizing antibodies equal to or
greater than 1:8 were defined as seropositivity [3,4,21,22].
Statistical Analysis
The accumulate incidence density of HFMD was calculated by
dividing the number of HFMD cases observed by the number of
observed person-years of this cohort from birth through October
2010. We used Chi-square testing and Fisher Exact testing to
analyze the categorical data, as appropriate. Neutralizing antibody
titers below 1:8 were assumed to be 1:4 and were log-transformed
to calculate the geometric mean titer (GMT) and 95% confidence
intervals. Antibody titers .1:2048 were assigned a value of 1:2048.
Hypothesis testing was conducted using two-sided tests and an
alpha value of 0.05 was taken to indicate statistically significant. All
statistical analyses were performed using SAS software, version 9.1
(SAS Institute Inc., Cary, NC, U.S.).
Results
Subjects
The cohort was first built in April 2007, with 1740 neonates
recruited. A total of 975 infants were followed up completely from
September 2007 to October 2010, including 548 boys and 427
girls with a sex ratio of 1.3:1. The average birth weight of the
infants was 3502.2 g. Blood samples were obtained from these
infants at 2, 7, 12, and 27–38 months of age. There were 555
infants whose mother’s blood samples were also available. The
mean age of the mothers was 24.8 years on the date of delivery.
Infection Spectrum of EV71 and/or CoxA16
Among the 975 infants, a total of 143 HFMD cases were
detected during the retrospective survey period from September
2007 to October 2010 (Figure 1), including 11 inpatients, 126
outpatients, and 6 patients whose families did not seek medical
intervention. However, only 16 out of 143 cases were reported to
the National Infectious Disease Information Management System
with a report rate of 11.2% (16/143). Among the 143 HFMD
cases, 99 (69.2%) and 90 (62.9%) cases had EV71 and CoxA16
neutralizing antibody titers increased at least 4-fold after illness,
respectively. There were 54 (37.8%) cases had at least 4-fold
increase in the two antibody titers, and only 8 (0.6%) cases had
neither EV71 nor CoxA16 neutralizing antibody titer increased
after illness. Other 695 infants were of non-HFMD infection with
EV71 and/or CoxA16, of which 414 (59.6%), 154 (22.1%), and
127 (18.3%) infants demonstrated positive antibody titers for both
EV71 and CoxA16, EV71 alone, and CoxA16 alone, respectively.
Although up to 85.9% (838/975) of the infants were infected by
EV71 and/or CoxA16 during the survey period, only a small
number of them showed clinical manifestations of HFMD, and
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survey period, only 137 (14.1%) infants were not infected with
EV71 or CoxA16.
Dynamic Changes in Seropositive Rate and Accumulate
Incidence Density
The seropositive rates of neutralizing antibody against EV71
and CoxA16 in prenatal women were 85.3% and 89.1% before
delivery, respectively (Table 1). The seropositive rates against
EV71 and CoxA16 in the infants at 2 months of age were 57.6%
and 39.5%, respectively, which decreased gradually to 41.3% and
26.4% at 7 months of age. Thereafter, the seropositive rates
remained relatively low from 7 to 12 months of age. However, a
moderate increase in the seropositive rate was observed at 27 to 38
months of age, with 56.2% and 54.3% seropositive rates against
EV71 and CoxA16, respectively, and more than 40% of infants
had EV71 and/or CoxA16 antibody titers of 1:32 or more
(Figure 2). A similar increase in GMTs was also found from 12 to
27–38 months of age, with EV71 antibody rising to 35.3 and
CoxA16 antibody rising to 54.3.
Among 143 HFMD cases recorded during the epidemiology
survey period, the first case was an infant aged 3 months and the
last case was an infant aged 34 months. Onset date of HFMD was
not available for 2 cases. These data yielded an accumulate
incidence density of 50.8/1000 person-years (95% CI: 43.0–59.6)
in the survey period (Figure 3). During the first 6 months after
birth, only 7 HFMD cases were detected, resulting in an
accumulate incidence density of 14.4/1000 person-years. The
accumulate incidence density reached 21.9/1000 person-years
during the first 9 months and held steadily around 21/1000
person-years until month 14. Thereafter, a significant rise in
accumulate incidence density was observed with 31.5/1000, 50.3/
1000 and 51.2/1000 person-years at 16, 22 and 25 months of age,
respectively.
Maternal Antibodies and the Occurrence of HFMD in
Their Infants
Among 555 infants whose mothers’ blood samples were
available, 473 were born to EV71-seropositive mothers and 82
to EV71-seronegative mothers, while 494 infants were born to
CoxA16-seropositive mothers and 61 to CoxA16-seronegative
mothers. No statistically significant difference in incidence
densities was observed between seronegative-mother-born infants
and seropositive-mother-born infants. However, serostatus of
EV71 antibody in these infants at 2 months of age showed a
significant impact on the incidence of HFMD: The EV71-
seronegative infants had a higher incidence (P=0.0228) than
EV71-seropositive infants. But no similar result was found
regarding serostatus of CoxA16 antibody (Table 2).
Discussion
Taiwan has set up HFMD surveillance systems based on both
physician and hospital to improve disease management since 1998
[21,23–25]. Mainland China is relatively backward in developing
HFMD cases report systems. HFMD was not included in the
notifiable communicable disease reporting system until 2008.
From this research, we found that HFMD cases reported to the
National Infectious Disease Information Management System
were far fewer than the actual number of HFMD cases. About
88.8% (127/143) of cases were not reported, highlighting the
importance of improving case management and enhancing the
Figure 1. Infection Spectrum of EV71 or CoxA16. 1 Reported cases of HFMD infections from National Infectious Disease Information
Management System. 2 Underreported cases of HFMD infections, went to hospital. 3 Underreported cases of HFMD infections, did not go to hospital.
4 Non-HFMD infections of EV71 or CoxA16. 5 Uninfected.
doi:10.1371/journal.pone.0037206.g001
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the high rate of underreporting may include: (1) The symptoms of
most cases were mild, and the doctors thought that HFMD was a
self-limited infection in infants. (2) The proportion of laboratory-
confirmed cases was very low due to unavailable funds and/or
facilities. (3) The government and doctors focused more on severe
cases, such as pulmonary edema, cardiac insufficiency, and
neurologic complications. Therefore, the outbreaks and epidemic
status of HFMD we perceived from the current surveillance system
was only a small portion of the actual disease burden, like the tip of
an iceberg.
In this study, the HFMD cases often lacked pathogenic
diagnoses. However, we can make an educated guess regarding
the possible prevalence of the pathogenic virus from the observed
at least 4-fold increase in the EV71 and CoxA16 neutralizing
antibodies before and after illness. The EV71 and CoxA16 were
found to be pathogenic virus for most cases of HFMD here.
We found that over 80% of pregnant women had positive serum
EV71 neutralizing antibodies, which was higher than the rates in
other Asian and Pacific regions [4], suggesting a higher prevalence
of EV71 in mainland China. Those infants with seropositive EV71
antibody at month 2 were found to be less likely to contract
HFMD. This could be attributed to transplacental maternal
antibodies. However, the serologic status of CoxA16 antibody
(seropositive or seronegative) did not seem to significantly affect
the occurrence of HFMD.
The significant increases in HFMD morbidity and mortality
have caused an enormous burden on public health. There are no
effective drugs or clinical treatments, and severe cases progress
rapidly. Development of a safe and effective vaccine has become
the most urgent task to prevent and control this disease. A national
program on developing EV71 vaccines has been initiated.
Selection of the target population is essential for the vaccine
development and the future immunization strategy. Previous study
suggested that infants after 6 months of age would be susceptible to
both EV71 and CoxA16 infection due to waning maternal
antibody, and the vaccines being developed should target infants
,6 months of age [4]. Our study showed that the infants aged 7 to
Figure 2. Reverse cumulative distribution curves of neutralizing antibody titers in infants at month 2, 7, 12, and 27–38.
doi:10.1371/journal.pone.0037206.g002
Table 1. Dynamic changes of the seropositive rates and GMTs of EV71 and CA16 neutralizing antibodies in mothers and their born
children at 2, 7, 12 and 27–38 months of age.
Neutralizing antibody Mother Month 2 Month 7 Month 12 Month 27–38
EV71 Seropositive rates % (95%CI)
85.3 57.6 41.3 42.2 56.2
(82.1–88.1) (54.5–60.8) (38.2–44.5) (39.0–45.3) (53.0–59.4)
GMTs (95%CI)
25.9 10.2 11.3 12.4 35.3
(23.4–28.7) (9.5–10.8) (10.3–12.5) (11.1–13.7) (30.8–40.5)
CoxA16 Seropositive rates % (95%CI)
89.1 39.5 26.4 30.5 54.3
(86.2–91.5) (36.4–42.6) (23.6–29.2) (27.6–33.5) (51.1–57.4)
GMTs (95%CI)
31.4 8.1 7.3 8.1 24.3
(28.4–34.8) (7.6–8.7) (6.8–7.8) (7.5–8.8) (21.5–27.4)
doi:10.1371/journal.pone.0037206.t001
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and the incidence of HFMD remained a low level till month 14,
which suggest that infants over 14 months of age would be most
susceptible to HFMD. It could be assumed that infants aged 6 to
14 months should have the first priority to receive EV71 vaccine.
Considering there are already many doses in routine vaccination
within the first 6 months after birth, if we want to apply the EV71
vaccine in the infants under 6 months of age, concomitant
administration of EV71 vaccine with current routine pediatric
vaccines needs to be assessed in future clinical trial with EV71
vaccine.
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